Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Epizyme's Return On Capital Employed Insights

Epizyme (NASDAQ:EPZM) brought in sales totaling $8.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.58%, resulting in a loss of $55.51 million. Epizyme collected $11.58 million in revenue during Q4, but reported earnings showed a $50.65 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.